K2P5.1 has been shown to control diverse physiological and pathophysiological processes including innate immunity and cancer progression (Bittner et al., 2010b; Clark et al., 2011; Cid et al., 2013), and is, therefore, expected to become a potential therapeutic target for the treatment of autoimmune, inflammatory, and allergic diseases as well as several types of cancers. The gene discussed is KCNK5; the disease is cancer.